NCT05138705View on ClinicalTrials.gov

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

PHASE4CompletedINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

August 5, 2022

Conditions

Influenza, Human

Interventions

BIOLOGICAL

Quadrivalent Influenza Virus Split Vaccine

0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains

Trial Locations (1)

Unknown

Tingting and Yu, Tai’an

All Listed Sponsors

lead

Shanghai Institute Of Biological Products

INDUSTRY

NCT05138705 - Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years | Biotech Hunter | Biotech Hunter